Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations

Mostrar otras versiones (1)

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the progression of chronic kidney disease (CKD). These agents prevent decline in kidney function through reduction in glomerular hypertension mediated through tubuloglomerular feedback independent of their effect on glycemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yau, Kevin, Dharia, Atit, Alrowiyti, Ibrahim, Cherney, David Z.I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263228/
https://www.ncbi.nlm.nih.gov/pubmed/35812300
http://dx.doi.org/10.1016/j.ekir.2022.04.094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263228/
https://www.ncbi.nlm.nih.gov/pubmed/35812300
http://dx.doi.org/10.1016/j.ekir.2022.04.094

Ejemplares similares